Resolution of primary acquired melanosis with atypia after treatment with topical mitomycin C and interferon alfa-2b

Message:
Abstract:
Purpose
To report a case of primary acquired melanosis (PAM) successfully treated with combined topical mitomycin C and interferon-α2b.Case Report: A 75-year-old man presented with an extensive unilateral pigmented lesion involving 360° of the bulbar conjunctiva, extending to the fornices and palpebral conjunctiva. Map biopsy confirmed PAM with local atypia. Treatment was initiated with mitomycin C 0.04% eye drops for two courses. Although the lesion markedly responded to the treatment, residual lesions justified further therapy. To avoid ocular surface toxicity induced by excessive mitomycin C exposure, interferon-α2b eye drops were started and continued for 6 months. The pigmented lesion almost completely disappeared and no significant complication or recurrence was observed for 24 months.
Conclusion
Combination therapy using mitomycin C and interferon-α2b for PAM with atypia may be recommended as an effective treatment modality, avoiding the ocular surface toxicity due to excessive mitomycin C exposure.
Language:
English
Published:
Journal of Ophthalmic and Vision Research, Volume:10 Issue: 1, Jan-Mar 2015
Page:
84
magiran.com/p1403165  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!